13 July 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut allergy which is designed to be safe, effective and convenient, shared further data from a follow up study of PVX108 Phase 1 trial subjects at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2021 in Krakow, Poland. Aravax Chief Scientific Officer Sara Prickett presented early data from longitudinal studies of Phase 1 tr